Note: Ingredients listed on restricted chemical lists
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
General Information
Version
0
Revision date
2024-03-06
Product name
Heparin Sodium 0.45% Sodium Chloride Injection
Product name
Heparin Sodium 0.45% Sodium Chloride Injection
Identification on the label/Trade name
Heparin Sodium 0.45% Sodium Chloride Injection | Manufacturer | Revison 03/06/2024
Product Synonyms
Heparin Sodium 0.45% Sodium Chloride Injection (freeflex®)
Icons in SDS
Company Information
company name
Fresenius Kabi USA, LLC
Section 2
SECTION 2: Hazards identification
GHS Class Not classified Emergency Overview This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.
Principle Routes of Exposure
Inhalation Ingestion Eye contact Skin Absorption. Injection.
Potential health effects
Eye Contact with eyes may cause irritation. Skin May cause skin irritation. Inhalation May cause irritation of respiratory tract. Ingestion May cause irritation. Signs/Symptoms Adverse reactions from prescribed doses include: hemorrhage, local irritation, erythema, mild pain, hematoma, ulceration, hypersensitivity reactions (chills, fever, urticaria), asthma, rhinitis, lacrimation, headache, nausea, vomiting, anaphylactic reactions including shock, itching, burning, and thrombocytopenia. The chief sign of heparin overdose is bleeding (nosebleeds, blood in urine, tarry stools, easy bruising, or petechial formations). When clinical circumstances require reversal of heparinization, protamine sulfate should be administered. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Individuals with documented hypersensitivity to heparin sodium and individuals with thrombocytopenia Conditions or increased risk for hemorrhage.
